Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04323098




Registration number
NCT04323098
Ethics application status
Date submitted
24/03/2020
Date registered
26/03/2020
Date last updated
4/04/2024

Titles & IDs
Public title
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
Scientific title
A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A Patients
Secondary ID [1] 0 0
270-303
Universal Trial Number (UTN)
Trial acronym
GENEr8-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - valoctocogene roxaparvovec

Experimental: valoctocogene roxaparvovec - Single administration of valoctocogene roxaparvovec at a dose of 6E13 vg/kg with prophylactic corticosteroids


Other interventions: valoctocogene roxaparvovec
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in FVIII Activity as Measured by Chromogenic Substrate Assay at Week 52.
Timepoint [1] 0 0
Baseline to Week 52
Secondary outcome [1] 0 0
Change From Baseline in Annualized Utilization of Exogenous FVIII Replacement Therapy in EEP
Timepoint [1] 0 0
Baseline to efficacy evaluation period (EEP)
Secondary outcome [2] 0 0
Change From Baseline in the Annualized Number of Bleeding Episodes Irrespective of Exogenous FVIII Replacement Treatment (Annualized Bleeding Rate, ABR for All Bleeds) in EEP
Timepoint [2] 0 0
Baseline to efficacy evaluation period (EEP)
Secondary outcome [3] 0 0
Change From Baseline in the Annualized Number of Bleeding Episodes Requiring Exogenous FVIII Replacement Treatment (ABR for Treated Bleeds) in the EEP.
Timepoint [3] 0 0
Baseline to EEP
Secondary outcome [4] 0 0
Change From Baseline in Haemo-QoL-A Quality of Life: Total Score at Week 52
Timepoint [4] 0 0
Baseline to Week 52
Secondary outcome [5] 0 0
Change From Baseline in Haemo-QoL-A Quality of Life: Physical Functioning Domain Score, at Week 52
Timepoint [5] 0 0
Baseline to Week 52
Secondary outcome [6] 0 0
Change From Baseline in Haemo-QoL-A Quality of Life: Consequences of Bleeding Domain Score, at Week 52
Timepoint [6] 0 0
Baseline to Week 52
Secondary outcome [7] 0 0
Change From Baseline in Haemo-QoL-A Quality of Life: Role Functioning Domain Score, at Week 52
Timepoint [7] 0 0
Baseline to Week 52

Eligibility
Key inclusion criteria
1. Males >= 18 years of age with hemophilia A and residual FVIII levels <= 1 IU/dL as
evidenced by medical history, at the time of signing the informed consent.

2. Must have been on prophylactic hemophilia therapy for at least 12 months prior to
study entry. High-quality, well-documented historical data concerning bleeding
episodes and hemophilia therapy usage over the previous 12 months must be available.

3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure
days (EDs).

4. Willing and able to provide written, signed informed consent after the nature of the
study has been explained and prior to any study-related procedures.

5. No previous documented history of a detectable FVIII inhibitor, and results from a
Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda
Units (BU) (or less than 1.0 BU for laboratories with a historical lower sensitivity
cutoff for inhibitor detection of 1.0 BU) on 2 consecutive occasions at least one week
apart within the past 12 months (at least one of which should be tested at the central
laboratory).

6. Sexually active participants must agree to use an acceptable method of effective
contraception, either double-barrier contraception (ie, condom + diaphragm; or condom
or diaphragm + spermicidal gel or foam) or their female partner either using hormonal
contraceptives or having an intrauterine device. Participants must agree to
contraception use for at least 12 weeks post-infusion; after 12 weeks, participants
may stop contraception use only if they have had 3 consecutive semen samples with
viral vector DNA below the limit of detection.

7. Willing to abstain from alcohol consumption for at least the first 52 weeks following
BMN 270 infusion.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Participants with detectable pre-existing antibodies to the adeno-associated virus
(AAV5) capsid are excluded with the following exception: up to 25% of participants may
have detectable pre-existing AAV5 capsid antibodies with titer level below the minimum
required dilution (< 20).

2. Any evidence of active infection, including Coronavirus Disease (COVID-19), or any
immunosuppressive disorder, except for HIV infection. HIV-positive patients who meet
all other eligibility criteria may be included if they have a CD4 count > 200/mm^3 and
an undetectable viral load (unquantifiable viral load as defined as less than the
limit of quantification by the testing laboratory's assay is permitted) while
receiving an antiretroviral therapy (ART) regimen that does not contain efavirenz or
another potentially hepatotoxic ART.

3. Significant liver dysfunction with any of the following abnormal laboratory results:
alanine aminotransferase (ALT) > 1.25x upper limit of normal (ULN);aspartate
aminotransferase (AST) > 1.25x ULN;gamma-glutamyltransferase (GGT) > 1.25x ULN;Total
bilirubin > 1.25x ULN;Alkaline phosphatase > 1.25x ULN; or international normalized
ratio (INR) >= 1.4.

Participants whose liver laboratory assessments fall outside of these ranges could
undergo repeat testing of the entire liver test panel within the same Screening window
and, if eligibility criteria are met on retest, could be enrolled after confirmation
by the Medical Monitor.

4. FibroScan or prior liver biopsy showing significant fibrosis of 3 or 4 as rated on a
scale of 0-4 on the Batts-Ludwig (Batts 1995) or METAVIR (Bedossa 1996) scoring
systems, or an equivalent grade of fibrosis if an alternative scale is used.

5. Evidence of any bleeding disorder not related to hemophilia A.

6. Platelet count of < 100 x 10^9/L.

7. Creatinine >= 1.5 mg/dL

8. Liver cirrhosis or other clinically significant liver disease of any etiology as
assessed by FibroScan or liver ultrasound.

9. Chronic or active hepatitis B as evidenced by positive serology testing (hepatitis B
surface antigen [HBsAg], hepatitis B surface antibody [HBsAb], and hepatitis B core
antibody [HBcAb]) and confirmatory hepatitis B virus (HBV) DNA testing. Refer to the
Centers for Disease Control (CDC) table for the interpretation of serological test
results in the Laboratory Manual.

10. Active Hepatitis C as evidenced by detectable hepatitis C virus (HCV) RNA or currently
on antiviral therapy.

11. Active malignancy, except non-melanoma skin cancer.

12. History of hepatic malignancy.

13. History of arterial or venous thromboembolic events (eg, deep vein thrombosis,
non-hemorrhagic stroke, pulmonary embolism, myocardial infarction, arterial embolus),
with the exception of catheter-associated thrombosis for which anti-thrombotic
treatment is not currently ongoing.

14. Known inherited or acquired thrombophilia, including conditions associated with
increased thromboembolic risk, such as atrial fibrillation.

15. Treatment with any investigational product within 30 days or 5 half-lives of the
investigational product prior to the screening period. For participants who have
received a prior investigational product, all ongoing adverse events (AEs) experienced
while receiving that investigational product must have resolved prior to screening for
this study.

16. Any condition that, in the opinion of the Investigator or Sponsor would prevent the
patient from fully complying with the requirements of the study (including possible
corticosteroids (CS) treatment and/or use of alternative immunosuppressive agents
(AIS) outlined in the protocol) and/or would impact or interfere with evaluation and
interpretation of participant safety or efficacy result.

17. Prior treatment with any vector or gene transfer agent.

18. Major surgery planned in the 52-week period following the infusion with BMN 270.

19. Use of systemic immunosuppressive agents, not including CS, or live vaccines within 30
days before the BMN 270 infusion.

20. Concurrent enrollment in another clinical study, unless it is an observational
(non-interventional) clinical study that does not interfere with the requirements of
the current protocol or have the potential to impact the evaluation of efficacy and
safety of BMN 270 and with prior consultation with the Medical Monitor.

21. Known allergy or hypersensitivity to BMN 270 investigational product formulation.

22. Unwilling to receive blood or blood products for treatment of an adverse event and/or
a bleeding episode.

Optional Liver Biopsy Inclusion and Exclusion Criteria

Individuals eligible for the optional liver biopsy must meet the following inclusion
criteria:

1. Able to sign informed consent and comply with requirements for the optional liver
biopsy

2. Documentation of FVIII activity >= 50 IU/dL (or higher, depending on local guidelines
and/or Investigator discretion) within 24 hours prior to the liver biopsy being
performed (FVIII activity levels should be assessed at the local laboratory).
Participants may be treated with additional exogenous FVIII replacement products in
order to increase their FVIII activity to an appropriate level, under the
supervision/instruction of the Investigator.

Individuals who meet the following exclusion criterion are not be eligible for the optional
liver biopsy:

1. Any condition that, in the opinion of the Investigator or a hepatologist/radiologist
would make liver biopsy contraindicated. This includes (but is not limited to)
abnormalities detected on liver ultrasound performed within 28 days of procedure, or prior
liver ultrasound result within 90 days that would preclude safe performance of the biopsy

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/12/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2027
Actual
Sample size
Target
Accrual to date
Final
22
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment hospital [3] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Fiona Stanley Hospital - Perth
Recruitment hospital [5] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Brisbane
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment postcode(s) [4] 0 0
- Perth
Recruitment postcode(s) [5] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Missouri
Country [3] 0 0
United States of America
State/province [3] 0 0
Ohio
Country [4] 0 0
Brazil
State/province [4] 0 0
Campinas
Country [5] 0 0
Brazil
State/province [5] 0 0
São Paulo
Country [6] 0 0
Taiwan
State/province [6] 0 0
Changhua
Country [7] 0 0
Taiwan
State/province [7] 0 0
Taichung

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BioMarin Pharmaceutical
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene
roxaparvovec in combination with prophylactic corticosteroids in patients with severe
hemophilia A.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04323098
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor, MD
Address 0 0
BioMarin Pharmaceutical
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries